Incyte's skin disease drug shows long-term symptom relief in late-stage trials

Incyte's skin disease drug shows long-term symptom relief in late-stage trials | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Companies Incyte Corp Follow Abbvie Inc Follow Novartis AG Follow Show more companies Povorcitinib is a once-daily pill that works by blocking JAK1, a protein involved in the inflammation that leads to painful abscesses and nodules. Treatment options for the condition are limited and are mainly injectable drugs. There are curr ...